Gastroenterology · Inflammatory Bowel Disease
The VIBRANT-IBD study explores a novel therapeutic approach for managing inflammatory bowel disease (IBD) through non-invasive vagus nerve stimulation. Successful outcomes could reshape treatment paradigms and influence portfolio strategies for companies focused on IBD therapies.
Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.
Last run 6/21/2026, 6:03:04 AM
Assessment confidence: 64% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.
The VIBRANT-IBD study explores a novel therapeutic approach for managing inflammatory bowel disease (IBD) through non-invasive vagus nerve stimulation. Successful outcomes could reshape treatment paradigms and influence portfolio strategies for companies focused on IBD therapies. Assessment grounded in 14 ranked evidence items (6 high-relevance).
If successful, this approach may lead to new treatment options, influencing portfolio strategies for companies focused on IBD therapies. The strongest clinical anchor is A Multicenter Observational Study to Understand the Clinical Characteristics, Treatment Patterns and Access to Novel Therapies of Patients With Diffuse Large B-Cell Lymphoma in the MEA Region (ClinicalTrials.gov), sponsor/company relevance (astrazeneca). In Gastroenterology · Inflammatory Bowel Disease, 0 regulatory and 5 competitive items passed relevance filtering for Nurosym.
The most relevant competitive pressure comes from [Ad hoc announcement pursuant to Art. (Roche) — sponsor/company relevance (roche). Secondary pressure from Bristol Myers Squibb Announces Phase 3 EXCALIBER-RRMM Study Evaluating Iberdomide in Combination with Standard Therapies Demonstrated Significant Improvement in Minimal Residual Disease Negativity Rat. This study could provide insights into novel therapeutic approaches for managing IBD, potentially impacting existing treatment paradigms.
Regulatory risk is concentrated around Positive results may prompt further clinical trials and regulatory submissions, affecting the approval landscape for new IBD therapies..
No evidence in this category.
A Multicenter Observational Study to Understand the Clinical Characteristics, Treatment Patterns and Access to Novel Therapies of Patients With Diffuse Large B-Cell Lymphoma in the MEA Region
ClinicalTrials.govhigh relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View sourceVIBRANT-IBD: Brain Effects of Non-Invasive Vagus Nerve Stimulation in IBD Remission
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourcePancreas Lipotoxicity in T2D: Edinburgh Diabetes Remission Study (EDRS)
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceCohort Study on Neuroimmune Diseases in the Reproductive Age
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source[Ad hoc announcement pursuant to Art.
Rochehigh relevance
Sponsor/company relevance (Roche)
FDA document
View sourceBristol Myers Squibb Announces Phase 3 EXCALIBER-RRMM Study Evaluating Iberdomide in Combination with Standard Therapies Demonstrated Significant Improvement in Minimal Residual Disease Negativity Rat
Bristol Myers Squibbhigh relevance
Sponsor/company relevance (Bristol Myers Squibb)
FDA document
View sourceBristol Myers Squibb Presents Encouraging Data from Phase 1 Breakfree-1 Study of CD19 NEX-T™ CAR T Cell Therapy in Three Chronic Autoimmune Diseases at ACR Convergence 2025
Bristol Myers Squibbhigh relevance
Sponsor/company relevance (Bristol Myers Squibb)
FDA document
View sourceBristol Myers Squibb Announces Continuation of ADEPT-2 Phase 3 Study in Psychosis Associated with Alzheimer's Disease
Bristol Myers Squibbhigh relevance
Sponsor/company relevance (Bristol Myers Squibb)
FDA document
View sourceRoche's ENSPRYNG shows 68% relapse reduction in Phase III MOGAD study
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
Effects of fecal microbiota transplantation and probiotics on the gut microbiome in antibiotic-treated septic patients: A pilot randomized controlled trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View sourceThe diameter of malformation capillaries does not influence the efficacy of photodynamic therapy for facial port-wine stains: a pilot study.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View sourceSustained on/off-treatment disease control with abrocitinib for moderate-to-severe atopic dermatitis.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View sourceGinger-based formulations for allergic rhinitis disease: a systematic review and meta-analysis of experimental studies in animals and humans.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View sourceSelf-assembled non-steroidal anti-inflammatory drug-peptide hydrogel to effectively mitigate ocular inflammation.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View sourcePrecedents · guidance
Loading regulatory precedents…
View full regulatory analysisCompetitors · threats
Loading competitive findings…
View full competitive analysisThe VIBRANT-IBD study explores a novel therapeutic approach for managing inflammatory bowel disease (IBD) through non-invasive vagus nerve stimulation. Successful outcomes could reshape treatment paradigms and influence portfolio strategies for companies focused on IBD therapies.
If the study demonstrates efficacy, it could lead to new product development opportunities and alter market dynamics for existing IBD treatments, potentially impacting revenue streams.
Positive results may prompt further clinical trials and regulatory submissions, affecting the approval landscape for new IBD therapies.
Monitor results from the MRI assessments and psychological questionnaires, as well as participant feedback on the intervention.
Track for follow-up milestones; no immediate action required.